| Jun 7 |
Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%
|
| Jun 6 |
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
|
| Jun 5 |
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
|
| Jun 5 |
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
|
| Jun 4 |
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
|
| Jun 4 |
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
|
| Jun 3 |
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
|
| Jun 3 |
Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround
|
| Jun 2 |
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
|
| May 31 |
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
|
